In December 2025, a randomized, double-blind, placebo-controlled clinical study was published in the Journal of Cosmetic Dermatology, evaluating orally administered heat-treated L. sakei proBio65® in healthy women aged 30 to under 50. Participants consumed a daily capsule for 8 weeks, and skin moisture and parameters of skin elasticity were assessed using validated dermatological instruments at 5 and 8 weeks. Interest in supporting skin health from within continues to grow, driven by expanding research on the gut–skin axis. Scientific evidence increasingly suggests that the intestinal microbiota plays a role in skin barrier function, hydration, and overall skin condition.
Among the nutritional approaches being explored are probiotics and postbiotics—including non-viable bacterial preparations designed to deliver functional benefits with improved stability and consistency.
Postbiotics and Skin Health
Latilactobacillus sakei proBio65® is a patented lactic acid bacteria strain originally isolated from traditional fermented vegetables. Previous research has examined this strain in both live and heat-treated formats, contributing to interest in its use for skin-focused dietary supplement applications. Postbiotics, which consist of non-viable microbial cells or their components, offer formulation advantages over live probiotics, including greater stability and predictable dosing without the need to maintain bacterial viability.
New Clinical Evidence
In December 2025, a randomized, double-blind, placebo-controlled clinical study was published in the Journal of Cosmetic Dermatology, evaluating orally administered heat-treated L. sakei proBio65® in healthy women aged 30 to under 50.
Participants consumed a daily capsule for 8 weeks, and skin condition was assessed using validated dermatological instruments, including measurements of cheek moisture, transepidermal water loss (TEWL), and parameters of skin elasticity.
Per comment, on the TEWL text, you might consider the following as the opening text:
Key Findings
Select skin elasticity parameters improved more in the proBio65® group compared to baseline than placebo, with statistical significance observed at 5 weeks.
In a subgroup analysis of women in their 40s, the postbiotic group demonstrated greater improvements in cheek moisture compared to baseline than placebo, with enhanced skin elasticity benefits at 5 and 8 weeks
The postbiotic was well tolerated, with a safety profile comparable to placebo
Implications for Skin Health Formulations
These findings add to the growing body of research supporting postbiotics as a credible, science-based category within skin health nutrition. For brands and formulators seeking stable, clinically studied ingredients aligned with gut–skin axis research, L. sakei proBio65® offers a compelling option. It’s postbiotic format allows versatility in both oral and topical applications.
Learn more about L. sakei proBio65® or contact Kaneka Probiotics to explore formulation opportunities.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.